通过ACT随机对照试验对阿尔茨海默病的行为和生活方式干预的iImplementation Framework进行测试 (MOBILIZE)
Dereck L Salisbury1, F Vankee Lin2, Fang Yu3
1University of Minnesota School of Nursing, Minneapolis, MN, USA.
Scientific reports
|February 13, 2025
概括
动员框架改善了阿尔茨海默病 (AD) 试验中的干预出席率和安全性. 这种实施策略对于AD研究中的多地点行为干预研究至关重要.
科学领域:
- 神经科学是一个神经科学.
- 行为科学 行为科学
- 临床试验 临床试验
背景情况:
- 对阿尔茨海默病 (AD) 的多地点行为干预试验在剂量递送和认知结果方面面临挑战.
- 针对阿尔茨海默病的行为和生活方式干预措施的实施框架 (MOBILIZE) 是为了解决这些实施问题而开发的.
研究的目的:
- 系统地评估MOBILIZE框架的实施结果在3个地点的有氧运动和认知训练 (ACT) 试验中对AD.
- 在MOBILIZE框架内评估选,干预遵守和安全流程.
主要方法:
- 该研究评估了MOBILIZE实施结果,包括查持续时间,干预坚持 (出席率和剂量),以及不良事件.
- 从3个地点的ACT试验中收集了146名参与者的数据,招聘从2018年4月开始.
主要成果:
- 从查到招生的中位时间为98天.
- 干预出席率平均为76.7%,100%遵守运动剂量为71.7%,认知剂量为51.5%.
- 报告了10个与研究相关的不良事件,表明安全性良好.
结论:
- 在ACT试验中,MOBILIZE框架促进了高干预出席率和安全性.
- MOBILIZE显示出作为早期阿尔茨海默病行为干预试验的有价值的实施策略的承诺.
相关概念视频
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
01:26Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429